linjc16/ctgov huggingface dataset:
Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles

Study Overview
=================
Brief Summary
-----------------
The aim is to explore whether the incidence of progesterone rise in the late follicular phase differs between GnRH-agonist and GnRH-antagonist protocols for IVF and whether this has an impact on the probability of pregnancy achievement.

Detailed Description
-----------------
In view of the current debate concerning possible differences in efficacy between the two GnRH analogues, the current study aimed to explore whether progesterone control in the late follicular phase differs when GnRH-agonist is used as compared to GnRH-antagonist and if so to what extend does the progesterone rise have an impact on the probability of achieving a pregnancy.

Official Title
-----------------
Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF

Conditions
-----------------
Pregnancy Outcome After In Vitro Fertilization (IVF)

Intervention / Treatment
-----------------
* Other: In vitro fertilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age < 39 follicle-stimulating hormone (FSH) < 12 gonadotropin dose 100-300IU Exclusion Criteria: endometriosis known endocrine disorder blood analyzed in another laboratory

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antagonist group<br>Antagonist protocol for IVF | Other: In vitro fertilization<br>* In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation<br>* Other names: progesterone;|
| Active Comparator: Agonist group<br>Long Agonist protocol for IVF | Other: In vitro fertilization<br>* In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation<br>* Other names: progesterone;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of late progesterone rise on the day of HCG triggering |  | Up to delivery (2010) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate Delivery rate |  | Up to delivery (2010) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
progesterone
National Cooperative Growth Study in CKD

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.

Official Title
-----------------
National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End-Stage Renal Disease (ESRD)

Conditions
-----------------
Growth Hormone Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney Disease Exclusion Criteria: Greater than 18 years old Not a patient at the UC Davis Medical Center pediatric clinic

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated. |  | per the study, the pt will be on GH treatement until the physician instructs them to stop | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Growth Failure AND, Chronic Renal Insufficiency OR, End Stage Renal Disease
Bevacizumab and Vasoconstriction

Study Overview
=================
Brief Summary
-----------------
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.

Official Title
-----------------
Bevacizumab and Vasoconstriction

Conditions
-----------------
Hypertension, Cancer

Intervention / Treatment
-----------------
* Drug: Bevacizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male 18-50 years old normal results of glucose, lipids and creatinine informed consent Exclusion Criteria: History of abuse of drugs or alcohol History of malignant disease First degree relatives with a history of cancer before the age of 50 First degree relatives with a history of premature cardiovascular disease Current use of medication Clinical evidence of cardiac of pulmonary disease Hypertension ( systolic>140mmHg, diastolic >90mmHg) Diabetes mellitus smoking a history of thombosis or a family history of recurrent thrombosis abnormality on ECG

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bevacizumab<br> | Drug: Bevacizumab<br>* Intra-arterial infusion during 6 minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio |  | Infusion of bevacizumab during 6 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between VEGF concentrations in plasma and the vasoconstrictive response to bevacizumab |  | Infusion of bevacizumab during 6 minutes |
Effect of Testosterone Treatment on Drug Metabolism and Transport

Study Overview
=================
Brief Summary
-----------------
This project will evaluate the effect of gender-affirming testosterone treatment on how other medications are processed by the body.

Detailed Description
-----------------
Gender-affirming hormone therapy may include testosterone, a hormone that the body creates and uses naturally. Testosterone is prepared as a medication that patients may take to increase hormone levels. Changes in testosterone concentrations in the body may affect how the body processes other medicines. The purpose of this study is to find out how testosterone therapy affects a single tracer dose of approved medicines in the blood (midazolam, digoxin, and acetaminophen) and to confirm testosterone treatment does not affect natural bacterial in the gut.

Official Title
-----------------
Effect of Gender-Affirming Testosterone Therapy on Drug Metabolism, Transport, and Gut Microbiota

Conditions
-----------------
Transgender Persons

Intervention / Treatment
-----------------
* Drug: Midazolam oral solution
* Drug: Digoxin Oral Tablet
* Drug: Acetaminophen Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self-identified trans* adult at least 18 years of age. Not taking testosterone treatment currently. Planning to start testosterone treatment through care provider for gender-affirming medical care. Exclusion Criteria: Unwilling/unable to return for project follow-up visits. Unwilling/unable to provide written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Midazolam oral solution|Oral syrup|
|Drug: Digoxin Oral Tablet|Oral tablet|
|Drug: Acetaminophen Oral Tablet|Oral tablet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| midazolam AUC ratio (treatment/control) | ratio of the area under of the plasma concentration time curve (AUC) of midazolam in the presence to absence of gender-affirming testosterone treatment. | 0-48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| midazolam Cmax ratio (treatment/control) | ratio of the maximum plasma concentration (Cmax) of midazolam in the presence to absence of gender-affirming testosterone treatment | 0-48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Testosterone Treatment
Cervicobrachial Neuralgia and Sagital Balance of the Cervical Spine

Study Overview
=================
Brief Summary
-----------------
The aim of this observational study is to establish estimation of global lordosis of the cervical spine (from C3 to C7) in patients with cervicobrachial neuralgia.

Detailed Description
-----------------
The main judgement critearia is the estimation in degree of this lordosis measured on EOS radiographies, The study includes adults patients with non traumatic cervicobrachial neuralgia caused by discal hernia free from any previous spine surgery.

Official Title
-----------------
Cervicobrachial Neuralgia and Sagital Balance of the Cervical Spine

Conditions
-----------------
Cervicobrachial Neuralgia, Lordosis

Intervention / Treatment
-----------------
* Diagnostic Test: Spine teleradiography EOS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (>18 years old) Suffering of cervicobrachial neuralgia caused by cervical hernia on MRI diagnosed by a neurosurgeon with social care rights Exclusion Criteria: Post traumatic cervicobrachial neuralgia in the past 12 months Anteriority of spine surgery Pregnant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Spine teleradiography EOS|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Low Cervical spine lordosis | In degree, the angle between the lower plate of C2 and the lower plate of the last cervical vertebrea (physiologycally) | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NDI | Pain questionnaires (score of 0 and 50) | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervicobrachial neuralgia, sagittal balance, lordosis
Prospective Melanoma Database

Study Overview
=================
Brief Summary
-----------------
In research on melanoma, translational research is the essential link between basic research and clinical research by facilitating the passage between discovery and improvement in the quality of patients care.That is the reason why it is very important to collect, and centralize clinical and biological data of patients with melanoma. The aim of the project is to provide to scientific community a structured, mixed clinical and biological database, unique in France, in order to insure accessibility to clinical data.

Detailed Description
-----------------
collection of clinical and biological data from patients with melanomas of any stage in a structured and centralized database

Official Title
-----------------
Creation of a Prospective Melanoma Database

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Other: clinical biological data collection on melanoma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Histologically confirmed melanoma of any stage Affiliated to a social security system in france Who signed the informed consent Exclusion Criteria: Any psychiatric or medical condition that would make the patient unable to give a signed informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Database of patients with melanoma |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
melanoma clinical biological database
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers

Study Overview
=================
Brief Summary
-----------------
The use of a suction blister apparatus has facilitated study of the immunologic capacity of human epidermal cells. We have been able to prepare purified populations of these cells after blister formation. Specifically, using the blister tops, we are able to enrich for epidermal Langerhans cells which are very potent stimulators in antigen presenting assays. Thus, this normal volunteer study provides an important source of fresh epidermal tissue from which we can study normal epidermal Langerhans cell function. In addition, we have recently used blister roofs in important experimental models of HIV-1 transmission. There is no other method available for assessing the biologic function of freshly isolated Langerhans cells without altering their milieu. It is a very safe and effective way to obtain human epidermal samples.

Detailed Description
-----------------
The use of a suction blister apparatus has facilitated study of the immunologic capacity of human epidermal cells. We have been able to prepare purified populations of these cells after blister formation. Specifically, using the blister tops, we are able to enrich for epidermal Langerhans cells which are very potent stimulators in antigen presenting assays. Thus, this normal volunteer study provides an important source of fresh epidermal tissue from which we can study normal epidermal Langerhans cell function. In addition, we have recently used blister roofs in important experimental models of HIV-1 transmission. There is no other method available for assessing the biologic function of freshly isolated Langerhans cells without altering their milieu. It is a very safe and effective way to obtain human epidermal samples.

Official Title
-----------------
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers

Conditions
-----------------
Dermatitis, Healthy, Neoplasm, Urticaria, Vesiculobullous Skin Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA Patients with urticaria of all types, blistering diseases, inflammatory dermatoses and neoplastic skin diseases. Patients 18 years of age or older. No pregnant women.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blister Formation, Inflammatory Mediator Assay, Ultraviolet Radiation
Cobalamin Deficiency - Diagnosis and Therapy

Study Overview
=================
Brief Summary
-----------------
In a retrospective study with existing values of vitamin B12 and holotranscobalamin 4 strategies are simulated and the results and costs are compared. Generally, cobalamin ist substituted by intramuscular administration. However, oral preparations are also available. Aims of the focus groups are to investigate the awareness of a (potential) deficiency and to identify a therapy for best adherence.

Detailed Description
-----------------
Various diagnostic strategies exist for the identification of a cobalamin deficiency. In a retrospective study with existing serum values of vitamin B12 and holotranscobalamin 4 strategies are simulated and the results and costs are compared. A cobalamin deficiency can have various causes: Dietary habits (vegetarian, vegan), advanced age, pernicious anaemia, gastrectomy, drug interactions (metformin, proton pump blocker). Therapy is often performed by intramuscular administration of cobalamin. However, oral preparations are also available in very different dosages. Investigators want to investigate with focus groups whether different patient groups are aware of a (potential) deficiency, how cobalamin is actually substituted (with registered or otherwise acquired products) and which therapy would lead to best adherence.

Official Title
-----------------
Diagnostics and Therapy of a Cobalamin Deficiency

Conditions
-----------------
Vitamin B 12 Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: potential cobalamin deficiency Exclusion Criteria: refusal to take part in a survey
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic strategies | Sensitivity and specificity of 4 different diagnostic strategies compared to the simultaneous determination of vitamin B12 and holotranscobalamin. | 2017 - 2018 | 
| supplementation of cobalamin deficiency | Patient's awareness of a potential cobalamin deficiency, treatment actually applied - with or without registration, ideal supplementation to achieve best adherence. | 2020 |
Anisometropia Amblyopia Improved by Perceptual Learning and Patching

Study Overview
=================
Brief Summary
-----------------
To compare the effects of perceptual learning with patching on improving visual acuity and contrast sensitivity in payient with anisometropic amblyopia.

Detailed Description
-----------------
Patients with anisometropic amblyopia were randomized to patching or perceptual learning group. Corrected amblyopic logMAR visual acuity and contrast sensitivity function were measured at four-weekly intervals until visual acuity stabilized or amblyopia resolved. Improvement in visual acuity, contrast sensitivity, and the resolution of amblyopia were compared between groups.

Conditions
-----------------
Anisometropic Amblypia

Intervention / Treatment
-----------------
* Procedure: computer program and patching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anisometropia without strabismus An interocular acuity difference of at least 0.2 logMAR in children (3-7 years of age) or in older children and adult patients without a history of patching or atropine penalization All patients wore their spectacle at least one year Exclusion Criteria: A history of prior spectacle correction A history of patching or optical penalization The existence of an ocular disease that could contribute to decreased visual acuity Learning difficulties The presence of strabismus

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: computer program and patching|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corrected amblyopic logMAR visual acuity and contrast sensitivity function |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
perceptual learning, occlusion therapy